KDVB (KDVB) News
Follow KDVB (KDVB) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 5 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
KDventures' AnaCardio Raises €62.5 Million
Kdventures AB OMXSTO:KDV_B
NEWS | Sep 30, 2026, 06:15 AM UTC
L
KDventures AB (KDV_B) Writes Down AnaCardio Stake After €62.5M Raise
KDventures said AnaCardio raised €62.5M in Series B at a lower valuation; KDV will not participate and will cut carrying value to ~SEK 30.6M, a ~SEK 30.0M (49.5%) negative adjustment with no cash flow impact.Material Det
NEWS | Sep 30, 2026, 06:11 AM UTC
L
KDventures’ portfolio company Umecrine Cognition reports last patient out in Phase 1b/2a study evaluating golexanolone in primary biliary cholangitis
STOCKHOLM, Sweden, September 15, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that its portfolio company Umecrine Cognition has reported that the last patient has completed the final follow-up visit in the
NEWS | Sep 15, 2026, 06:30 AM UTC
M
KDventures gains NCE protection through 2042, broadening commercial upside
A Redeye analyst published a Research Note on KDventures, highlighting that Umecrine Secured NCE protection through 2042.
EQUITY | Sep 07, 2026, 04:04 PM UTC
L
Kdventures gets two USPTO notices of allowance for Umecrine Cognition patent applications
Kdventures AB said its Umecrine Cognition patent applications received two USPTO notices of allowance.
EQUITY | Sep 07, 2026, 07:18 AM UTC
M
Umecrine Cognition gets two US Notices of Allowance on GAMSA compounds
KDventures AB says its portfolio company Umecrine Cognition received two Notices of Allowance from the USPTO for patent applications covering two second-generation GAMSA compound candidates.
EQUITY | Sep 07, 2026, 07:05 AM UTC
L
Kdventures carries out directed issue involving Modus Therapeutics
Kdventures AB says Modus Therapeutics carries out a directed issue. Details of size, pricing, and terms were not provided in the feed.
EQUITY | Sep 04, 2026, 11:09 AM UTC
L
Modus Therapeutics completes directed issue raising MSEK 7.6
KDventures AB says its portfolio company Modus Therapeutics carried out a directed issue of MSEK 7.6. Net proceeds will finance the 2027 development plan for sevuparin.
EQUITY | Sep 04, 2026, 11:05 AM UTC
L
Life sciences investor KDventures Q2 net loss widens
KDventures reported a wider net loss for Q2 tied to portfolio revaluations.
EARNINGS | Aug 28, 2026, 06:13 AM UTC
L
KDV_B: Sharp portfolio revaluations drove a significant net loss and lower NAV, despite clinical progress
KDV_B: Sharp portfolio revaluations drove a significant net loss and lower NAV, despite clinical progress
EQUITY | Aug 28, 2026, 06:03 AM UTC
L
KDVB Interim Report for January–June 2026
KDVB issued an interim report covering January–June 2026.
EQUITY | Aug 28, 2026, 06:00 AM UTC